Your Global Leader in Stem Cell Market Research
The global cord blood banking industry has been rapidly maturing in recent years. In part, this has been caused by changes in processing, storage, and transplantation technologies. These changes require executives and industry decision-makers to have a firm understanding of emerging trends.
One of the most notable cord blood industry trends has been a diversification of services. Put simply, cord blood banks are becoming diversified stem cell biobanks. [Read more…]
In addition to cord tissue storage, many cord blood banks are now investigating the addition of adipose-derived stem cell storage.
It is a logical product extension for cord blood banks, given that a range of collection, processing, and storage equipment is already present within the facility.
Additionally, conversion costs to allow for adipose-derived stem cell storage can be as low as USD $100,000 to $150,000.
The conversion of a cord blood facility to be able to offer adipose-derived stem cell storage can be efficiently accomplished through collaboration with a specialist in the area of adipose tissue extraction and storage.
Companies such as American Cryostem in the United States have been willing to partner with cord blood banks to assist them with adding adipose-derived MSC storage as a service.
Below is an analysis of both diversified cord blood banks and specialty companies that currently offer adipose-derived stem cell storage. [Read more…]
This article is part two of my interview with Matthew Feshbach, CEO and Co-Founder of Okyanos (pronounced “Oh – key – AH – nos”). Founded in 2011, Okyanos specializes in treating patients with chronic, degenerative conditions. Located in Freeport, Grand Bahama, just 55 miles from the United States, Okyanos Cell Therapy combines a blend of stem and regenerative cells derived from a patient’s own adipose (fat) tissue.
Treatment is performed in their state-of-the-art surgical center by a team of U.S. licensed medical doctors. Okyanos is also fully licensed under the Bahamas Stem Cell Therapy and Research Act and adheres to U.S. surgical center standards.
Using technology from Cytori Therapeutics, the company offers a highly characterized cellular product that is administered via a robust protocol by a renowned medical team within a world-class facility. It is my opinion, that Okyanos is a company that is setting the standard for others practicing cellular therapy with adipose-derived stem and regenerative cells.
The mesenchymal stem cell industry is well-known for its shifting dynamics, including new alliances, new research advances and innovations. Every month there are major new events that affect market participants.
While it may be possible to stay informed about mesenchymal stem cell industry news in your region, it can be more difficult to track changes on a global scale. For that reason, the following is a summary of significant mesenchymal stem cell industry events for June 2015.
